NewcelX Appoints Dr. Julien Boisdron to Advisory Board

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 12 Jan 26

Source: Newsfilter

NewcelX AG's stock surged by 14.61% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.

The company has appointed Dr. Julien Boisdron, a diabetes expert, to its Scientific Advisory Board. His extensive experience in diabetes treatment will provide strategic guidance for NewcelX's IsletRx program, which focuses on developing stem-cell-derived islet cell therapy for Type 1 Diabetes. This appointment is expected to enhance the company's competitiveness and advance its clinical trial processes.

Dr. Boisdron's involvement is anticipated to strengthen NewcelX's strategic direction in cell therapy, facilitating the global commercialization of innovative treatments. His expertise will help integrate patient needs with health system requirements, positioning NewcelX favorably in the metabolic and regenerative medicine landscape.

NCEL

$2.55+Infinity%1D

Analyst Views on NCEL

About NCEL

NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

NewcelX Appoints Dr. Julien Boisdron to Advisory Board

Analyst Views on NCEL

About NCEL

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Paramount Gold's Grassy Mountain Project Receives Approval

Aluminum Corp. of China to Acquire Controlling Stake in Brazilian Aluminum Producer

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch